

Ant
C7 disease, Hirschsprung's disease, colonic carcinoma, inflammatory bowel disease, ulcerative colitis, prediverticular disease of the colon, and colonic diverticulitis.

REMARKS**In the Claims:**

Claims 34 and 55 have been amended. Support for the newly added claims may be found in the application as originally filed.


Specifically, support for the amendment to claims 34 and 55 may be found in paragraph numbers 0149 to 0153, and throughout the application as originally filed.

No new matter has been added. Applicants believe that all of the pending claims before the Examiner are in condition for allowance. An early Office Action to that effect is, therefore, earnestly solicited.

If any fee is due in connection herewith not already accounted for, please charge such fee to Deposit Account No. 19-3880 of the undersigned. Furthermore, if any extension of time not already accounted for is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to the above-stated Deposit Account.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: March 28, 2003

CASE D0039 NP

VERSION WITH MARKINGS TO SHOW CHANGES MADE**In The Claims:**

Amend Claims 34 and 55.

34. ([New]Once Amended) A method of screening for candidate compounds capable of modulating the activity of a G-protein coupled receptor polypeptide, comprising:

- (a) contacting a test compound with a cell or tissue comprising an expression vector capable of expressing a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2, or encoded by ATCC deposit PTA-2682, under conditions in which said polypeptide is expressed; and
- (b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide,

wherein said candidate modulating compounds are useful for the treatment of a [lung] colon disorder.

55. ([New]Once Amended) The method according to claim 34 wherein said candidate compound is useful for treating [pulmonary]colon disorders selected from the group consisting of: [lung cancer; bronchopulmonary dysplasia; Pancoast tumors; and post-inflammatory pseudotumor] colon cancer; Crohn's disease, Hirschsprung's disease, colonic carcinoma, inflammatory bowel disease, ulcerative colitis, prediverticular disease of the colon, and colonic diverticulitis.